Crohn's disease trials in South Korea

In South Korea 30 Also abroad 422

30 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
Where
Ansan-si, Busan, Daegu, Daejeon, Dongjak-gu, Haeundae-gu, Seoul, Suwon, Wŏnju
Age
16 years to 80 years
People
1,200 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06430801 · EU 2023-508636-61-00
Phase 3Taking people
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
Where
Busan, Daegu, Seoul
Age
2 years to 17 years
People
120 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT05923073 · EU 2023-504735-41-00
Phase 3Taking people
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
Where
Seoul
Age
3 years to 64 years
People
196 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06663332 · EU 2023-509560-16-00
Phase 2/3Taking people
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
Where
Busan, Daegu, Daejeon, Dongdaemun-gu, Seongnam-si, Seoul, Suwon
Age
18 years and over
People
1,092 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07196722 · EU 2025-521382-27-00
Phase 3Taking people
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
Where
Busan, Daejeon, Ganggu, Seoul
Age
18 years and over
People
460 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07577843 · EU 2026-525922-39-00
Phase 2Taking people
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
Where
Busan, Daegu, Seoul, Wŏnju
Age
18 years to 75 years
People
268 worldwide
Run by
Takeda
See details and how to joinNCT06233461 · EU 2023-506704-14-00
Phase 3Taking people
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
Where
Ansan-si, Daegu, Gwangju, Seoul
Age
16 years to 80 years
People
425 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06819891 · EU 2024-513054-30-00
Phase 3Taking people
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Where
Ansan-si, Busan, Daegu, Daejeon, Gwangju, Seoul, Suwon
Age
16 years to 80 years
People
980 worldwide
Run by
Sanofi
See details and how to joinNCT07184931
Phase 3Taking people
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Where
Busan, Gwangju, Seoul
Age
16 years to 80 years
People
751 worldwide
Run by
Sanofi
See details and how to joinNCT07184944
Phase 3Taking people
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
Where
Daegu, Seoul
Age
2 years to 17 years
People
110 worldwide
Run by
AbbVie
See details and how to joinNCT05995353 · EU 2022-502050-14-00
Phase 3Taking people
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
Where
Busan, Daegu, Daejeon, Gangwon-do, Guri-si, Seoul
Age
16 years to 80 years
People
600 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06819878 · EU 2024-513053-69-00
Phase 3Taking people
A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
Where
Daegu, Seoul
Age
2 years to 17 years
People
70 worldwide
Run by
Takeda
See details and how to joinNCT06405087 · EU 2023-508804-39-00
Phase 3Taking people
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
Where
Deagu, Seoul
Age
2 years to 19 years
People
150 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT04844606
Phase 3Taking people
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
Where
Busan, Daegu, Seoul
Age
2 years to 17 years
People
90 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT05509777 · EU 2024-511472-32-00
Phase 2Taking people
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
Where
Busan, Daegu, Daejeon, Seoul
Age
18 years to 75 years
People
590 worldwide
Run by
AbbVie
See details and how to joinNCT06548542 · EU 2024-513009-30-00
Phase 1Taking people
A Phase 1 Study of ATORM-C in Patients With Crohn's Disease
Where
Seoul
Age
19 years to 80 years
People
18
Run by
ORGANOIDSCIENCES LTD.
See details and how to joinNCT07822087
Phase 3Taking people
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
Where
Daegu, Seoul
Age
2 years to 17 years
People
70 worldwide
Run by
Takeda
See details and how to joinNCT06100289 · EU 2023-503188-40-00
Phase 3Taking people
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
Where
Busan, Daegu, Daejeon, Seoul, Suwon
Age
18 years to 65 years
People
396 worldwide
Run by
Takeda
See details and how to joinNCT06227910 · EU 2023-509391-42-00
Phase 2Taking people
A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
Where
Haeundae, Wŏnju
Age
18 years to 75 years
People
192 worldwide
Run by
Takeda
See details and how to joinNCT06764615 · EU 2024-518914-18-00
Phase 3Taking people
A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
Where
Daegu, Incheon, Seoul
Age
2 years to 17 years
People
240 worldwide
Run by
Takeda
See details and how to joinNCT05442567 · EU 2023-509046-36-00
Phase 3Taking people
A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
Where
Daegu, Incheon, Seongnam, Seoul
Age
2 years to 17 years
People
120 worldwide
Run by
Takeda
See details and how to joinNCT04779320 · EU 2023-509045-13-00
No phaseTaking people
Predictors of Prognosis in IBD Patients
Where
Seongnam-si
Age
18 years and over
People
100
Run by
Seoul National University Bundang Hospital
See details and how to joinNCT05653011
No phaseTaking people
A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea
Where
Goyang-si
Age
18 years and over
People
600
Run by
Takeda
See details and how to joinNCT05428345
No phaseEnrolling by invitation
Research for the Precision Medicine in the Treatment of Inflammatory Bowel Disease
Where
Seoul
Age
10 years and over
People
2,000
Run by
Seoul National University Hospital
See details and how to joinNCT07166588
No phaseTaking people
SNU IBD Cohort Study : Searching for Characterization of High Risk Populations for Developing Inflammatory Bowel Disease
Where
Seoul
Age
10 years and over
People
500
Run by
Seoul National University Hospital
See details and how to joinNCT07011979